All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
The Lymphoma Hub Satellite Symposium at 15-ICML brought together an international panel of experts to discuss the novel chemotherapy-free treatment approaches for lymphoid malignancies. Professor Michael Hallek, University Hospital of Cologne, Cologne, DE, provided his thoughts on chemotherapy-free regimens for CLL.
Lymphoma Hub Satellite Symposium 2019 | CLL - chemotherapy-free regimens - Michael Hallek
The Alliance North American Intergroup Study (AO41202) did not find ibrutinib and rituximab to be better than rituximab and bendamustine. Prof. Hallek went on to present recent results from the CLL14 trials by the GCLLSG. In this study older or unfit patients benefited more from a chemotherapy-free treatment with obinutuzumab and venetoclax in terms of PFS than from chlorambucil and obinutuzumab (a summary of two abstracts presented at the 24th European Hematology Society (EHA) meeting and the 15-ICML are summarised here). In his concluding remarks, Prof. Hallek presented his recommendations regarding front-line CLL treatments:
He went on to advocate caution when using triplet combinations due to the higher risk of side effects.
Download Prof. Michael Hallek's slides:
These slides were presented by Prof. Michael Hallek during the first Lymphoma Hub Satellite Symposium at 15-ICML.Download as PDF
New chemotherapy-free approaches for the treatment of lymphoid malignancies
At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...
ASH 2018 | Ibrutinib plus rituximab provide superior outcomes than FCR in naïve CLL patients: Results from the ECOG-ACRIN phase III trial E1912
E1912 (NCT02048813) is a randomized, phase III trial that compared the efficacy and safety of...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox